Agios Pharmaceuticals (AGIO) News Today

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is getting attention ahead of its upcoming quarterly earnings report, which may be helping support the shares. Zacks said the company appears well positioned to beat earnings estimates for Q2, and HC Wainwright reiterated a Buy rating with a $52 price target while updating its long-term forecast.

• Positive Sentiment: Zacks highlighted Agios Pharmaceuticals as a potential earnings beat heading into Q2 results, suggesting expectations may be favorable ahead of the report. Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
• Positive Sentiment: HC Wainwright kept a bullish stance on Agios Pharmaceuticals (AGIO), maintaining a Buy rating and $52 target, which can reinforce investor confidence in the stock. HC Wainwright research note
• Neutral Sentiment: The same analyst firm made mixed EPS changes: it trimmed its FY2026 forecast slightly but raised estimates for FY2027 through FY2030, signaling a more constructive long-term outlook rather than a near-term catalyst. HC Wainwright earnings estimate updates
• Neutral Sentiment: Short-interest data showed 0 shares reported as shorted, which does not provide a meaningful bearish signal and is unlikely by itself to move the stock. Short interest update

Overall, AGIO appears to be trading with a mildly positive tone as investors look ahead to earnings and respond to supportive analyst commentary.